Overview

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects.
Phase:
Phase 1
Details
Lead Sponsor:
ContraFect